DE3524992A1 - Zusammensetzung zur inhibierung der ausloesung von akutem strahlungssyndrom an warmbluetern - Google Patents
Zusammensetzung zur inhibierung der ausloesung von akutem strahlungssyndrom an warmblueternInfo
- Publication number
- DE3524992A1 DE3524992A1 DE19853524992 DE3524992A DE3524992A1 DE 3524992 A1 DE3524992 A1 DE 3524992A1 DE 19853524992 DE19853524992 DE 19853524992 DE 3524992 A DE3524992 A DE 3524992A DE 3524992 A1 DE3524992 A1 DE 3524992A1
- Authority
- DE
- Germany
- Prior art keywords
- composition
- composition according
- warm
- approx
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 208000001395 Acute radiation syndrome Diseases 0.000 title claims description 9
- 206010068142 Radiation sickness syndrome Diseases 0.000 title claims description 9
- 230000002401 inhibitory effect Effects 0.000 title claims description 7
- 241001465754 Metazoa Species 0.000 claims description 20
- 206010040047 Sepsis Diseases 0.000 claims description 14
- 208000013223 septicemia Diseases 0.000 claims description 14
- 239000002158 endotoxin Substances 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 12
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 9
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 9
- 230000005855 radiation Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000284 endotoxic Toxicity 0.000 description 4
- 230000002346 endotoxic effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011785 NMRI mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000252983 Caecum Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/630,013 US4629722A (en) | 1984-07-12 | 1984-07-12 | Method of inhibiting the onset of acute radiation syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3524992A1 true DE3524992A1 (de) | 1986-01-16 |
| DE3524992C2 DE3524992C2 (OSRAM) | 1988-05-11 |
Family
ID=24525404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853524992 Granted DE3524992A1 (de) | 1984-07-12 | 1985-07-12 | Zusammensetzung zur inhibierung der ausloesung von akutem strahlungssyndrom an warmbluetern |
| DE3546592A Expired DE3546592C2 (OSRAM) | 1984-07-12 | 1985-07-12 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3546592A Expired DE3546592C2 (OSRAM) | 1984-07-12 | 1985-07-12 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4629722A (OSRAM) |
| JP (1) | JPS6193123A (OSRAM) |
| KR (1) | KR880000191B1 (OSRAM) |
| AU (1) | AU556971B2 (OSRAM) |
| BE (1) | BE902875A (OSRAM) |
| CH (1) | CH665355A5 (OSRAM) |
| DE (2) | DE3524992A1 (OSRAM) |
| FR (1) | FR2567403A1 (OSRAM) |
| GB (1) | GB2161381B (OSRAM) |
| IL (1) | IL75789A (OSRAM) |
| IT (1) | IT1214671B (OSRAM) |
| NL (1) | NL8501995A (OSRAM) |
| NZ (1) | NZ212691A (OSRAM) |
| ZA (1) | ZA855243B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US5354782A (en) * | 1991-01-17 | 1994-10-11 | Merrell Dow Pharmaceuticals Inc. | Polyamine phenols as radioprotective agents |
| AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
| US5530113A (en) * | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| WO2008153541A1 (en) | 2006-09-26 | 2008-12-18 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| JP6054942B2 (ja) | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
| AU2013262691B2 (en) | 2012-05-16 | 2018-12-20 | Immune Design Corp. | Vaccines for HSV-2 |
| EP3711768A1 (en) | 2013-04-18 | 2020-09-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL295025A (en) * | 2014-09-16 | 2022-09-01 | Bioincept Llc | Preparations and methods for the treatment of acute radiation syndrome |
| US11090355B2 (en) | 2015-08-28 | 2021-08-17 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
| EP3341739A4 (en) | 2015-08-28 | 2019-07-10 | BioIncept LLC | MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH |
| KR101909660B1 (ko) * | 2017-07-06 | 2018-10-18 | 이보미 | 안경알 자판기 서비스 제공 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3318568A1 (de) * | 1982-05-26 | 1984-01-12 | Ribi Immunochem Research, Inc.,, 59840 Hamilton, Mont. | Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, trehalosedimycolat und ein mit azeton ausgefaelltes nebenprodukt von mit chloroform-methanol extrahierten endotoxischen glykolipiden |
| DE3318567A1 (de) * | 1982-05-26 | 1984-01-12 | Ribi Immunochem Research, Inc.,, 59840 Hamilton, Mont. | Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, zellwandgeruest und trehalosedimycolat |
| DE3431058A1 (de) * | 1983-08-26 | 1985-03-07 | Ribi Immunochem Research, Inc., Hamilton, Mont. | Gereinigtes, entgiftetes endotoxin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1188519A (en) * | 1966-10-27 | 1970-04-15 | Wellcome Found | Method for the Purification of Lipopolysaccharides |
-
1984
- 1984-07-12 US US06/630,013 patent/US4629722A/en not_active Expired - Lifetime
-
1985
- 1985-07-09 NZ NZ212691A patent/NZ212691A/en unknown
- 1985-07-10 AU AU44758/85A patent/AU556971B2/en not_active Ceased
- 1985-07-11 NL NL8501995A patent/NL8501995A/nl not_active Application Discontinuation
- 1985-07-11 FR FR8510629A patent/FR2567403A1/fr not_active Withdrawn
- 1985-07-11 GB GB08517545A patent/GB2161381B/en not_active Expired
- 1985-07-11 ZA ZA855243A patent/ZA855243B/xx unknown
- 1985-07-12 CH CH3039/85A patent/CH665355A5/de not_active IP Right Cessation
- 1985-07-12 KR KR1019850004992A patent/KR880000191B1/ko not_active Expired
- 1985-07-12 JP JP60152571A patent/JPS6193123A/ja active Granted
- 1985-07-12 IT IT8548347A patent/IT1214671B/it active
- 1985-07-12 BE BE0/215338A patent/BE902875A/fr not_active IP Right Cessation
- 1985-07-12 IL IL75789A patent/IL75789A/xx unknown
- 1985-07-12 DE DE19853524992 patent/DE3524992A1/de active Granted
- 1985-07-12 DE DE3546592A patent/DE3546592C2/de not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3318568A1 (de) * | 1982-05-26 | 1984-01-12 | Ribi Immunochem Research, Inc.,, 59840 Hamilton, Mont. | Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, trehalosedimycolat und ein mit azeton ausgefaelltes nebenprodukt von mit chloroform-methanol extrahierten endotoxischen glykolipiden |
| DE3318567A1 (de) * | 1982-05-26 | 1984-01-12 | Ribi Immunochem Research, Inc.,, 59840 Hamilton, Mont. | Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, zellwandgeruest und trehalosedimycolat |
| DE3431058A1 (de) * | 1983-08-26 | 1985-03-07 | Ribi Immunochem Research, Inc., Hamilton, Mont. | Gereinigtes, entgiftetes endotoxin |
Also Published As
| Publication number | Publication date |
|---|---|
| NL8501995A (nl) | 1986-02-03 |
| DE3546592C2 (OSRAM) | 1988-06-01 |
| GB2161381B (en) | 1988-01-13 |
| FR2567403A1 (fr) | 1986-01-17 |
| CH665355A5 (de) | 1988-05-13 |
| US4629722A (en) | 1986-12-16 |
| NZ212691A (en) | 1988-02-12 |
| AU556971B2 (en) | 1986-11-27 |
| IT8548347A0 (it) | 1985-07-12 |
| DE3524992C2 (OSRAM) | 1988-05-11 |
| JPS6193123A (ja) | 1986-05-12 |
| KR880000191B1 (ko) | 1988-03-12 |
| KR860000867A (ko) | 1986-02-20 |
| GB8517545D0 (en) | 1985-08-14 |
| JPS6234733B2 (OSRAM) | 1987-07-28 |
| IL75789A (en) | 1990-04-29 |
| AU4475885A (en) | 1986-01-16 |
| BE902875A (fr) | 1985-11-04 |
| GB2161381A (en) | 1986-01-15 |
| IT1214671B (it) | 1990-01-18 |
| ZA855243B (en) | 1986-02-26 |
| IL75789A0 (en) | 1985-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3524992A1 (de) | Zusammensetzung zur inhibierung der ausloesung von akutem strahlungssyndrom an warmbluetern | |
| EP0392300B1 (de) | Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen | |
| DE3689363T2 (de) | Pharmazeutische Zusammensetzungen zur Behandlung der Metastasen von Krebstumoren. | |
| EP0453898B1 (de) | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen | |
| AT403122B (de) | Therapeutische infusionszubereitung auf basis von aminosäurederivaten | |
| DE2934069C2 (OSRAM) | ||
| DE3907649C2 (de) | Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung | |
| DE69715862T2 (de) | Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung | |
| CH654212A5 (de) | Zubereitung zur steigerung der therapeutischen wirkung eines antitumormittels und diese zubereitung enthaltende antitumor-zubereitung. | |
| EP0236390B1 (de) | Mittel gegen multiple sklerose | |
| DE69232516T2 (de) | Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung | |
| DE69103908T2 (de) | Verbessertes behandlungsverfahren für krebs. | |
| DE3875859T2 (de) | Zubereitungen zur verbesserung der adcc-therapien. | |
| EP0398165A1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| DE2523866A1 (de) | Schweisshemmendes mittel | |
| DE3000139A1 (de) | Die verwendung von glyzerinphosphorylderivaten in der therapie der dislipaemie, der hepatitis und vergleichgeeignete pharmazeutische kompositionen | |
| DE69328102T2 (de) | Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren | |
| DE2655690A1 (de) | Arzneimittelzubereitungen | |
| EP0256385B1 (de) | Verwendung von 15-Deoxyspergualin als Arzneimittel | |
| DE2328234C2 (de) | Zur systemischen Verabreichung geeignetes Mittel zur Inhibierung der Mobilisierung von Calciumphosphat | |
| AT392002B (de) | Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen | |
| AT408719B (de) | Mittel zur behandlung von hepatitis c | |
| DE3643001C2 (OSRAM) | ||
| DE2445679C3 (de) | Stimulierung der Immunität | |
| DE2110436C3 (de) | Verfahren zur Herstellung eines antileukopenischen und antikörperbildenden Thymusextrakts aus Kalbsthymus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3546592 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3546592 |
|
| AH | Division in |
Ref country code: DE Ref document number: 3546592 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| AH | Division in |
Ref country code: DE Ref document number: 3546592 Format of ref document f/p: P |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |